Stockscreener 앱 받기
18.82
2.79%
-0.54
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Why is Arcus Biosciences stock sliding today? By Investing.com - Investing.com Canada
Arcus Biosciences Prices $250 Million Common Stock Offering; Shares Down Pre-Bell - marketscreener.com
Arcus Biosciences reports $694M cash for pipeline advancement through pivotal trials - The Clinical Trial Vanguard
Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock - TradingView
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock - Yahoo Finance
Arcus Biosciences (RCUS) Shares Plunge Nearly 20% Amid Clinical Data Release and Stock Offering - GuruFocus
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance
Arcus Biosciences stock falls on public offering announcement - Investing.com
Arcus Biosciences slides 20% on stock offering, kidney-cancer data (RCUS:NYSE) - Seeking Alpha
Arcus Biosciences launches public offering of common stock By Investing.com - Investing.com Canada
Citi reiterates buy rating on Arcus Biosciences after stock drops 20% - StreetInsider
Arcus Biosciences launches public offering of common stock - StreetInsider
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm - Morningstar
Arcus Biosciences announces public stock offering - TradingView
A public stock offering has begun at Arcus Biosciences, but its size and completion remain uncertain. - Stock Titan
Arcus Biosciences Drops 5.5% After Truist Securities Maintains Buy - AlphaStreet
Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal - Yahoo Finance
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? - Zacks Investment Research
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research
Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead (NYSE:RCUS) - Seeking Alpha
Arcus stock rises on ARC-20 data for kidney cancer drug (RCUS) - Seeking Alpha
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer - BioSpace
Arcus Biosciences, Inc. (RCUS) Stock forecasts - Yahoo Finance UK
Arcus Biosciences Announces New Employment Inducement Grants - Yahoo Finance
Arcus Biosciences Drops 6.1% Amid Sector-Wide Selling - AlphaStreet
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo! Finance Canada
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance
Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage? - Yahoo Finance
Arcus Biosciences stock falls 2.79 percent before ARC-20 data - ad-hoc-news.de
Arcus Biosciences stock gains 1.49 percent ahead of data event - ad-hoc-news.de
Wall Street Zen upgrades Arcus Biosciences stock to Hold - ad-hoc-news.de
How Investors Are Reacting To Arcus Biosciences (RCUS) Expansive New Casdatifan ARC-20 Kidney Cancer Data - Yahoo Finance
Arcus Biosciences (RCUS) Pulls Back 3.13% to $24.44, Testing Key SupportBreak of Structure - siam.in
Arcus Biosciences, Inc. (RCUS) Stock forecasts - Yahoo Finance UK
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance
Wedbush Reiterates Arcus Biosciences At Outperform, Sets Price Target Of $43, Casdatifan Data Ahead - RTTNews
RCUS Reiterated by Wedbush -- Price Target Maintained at $43.00 - GuruFocus
Gilead Sciences Inc and Arcus Biosciences Inc Post ARC-7 Plenary Q&A Transcript - GuruFocus
Arcus Biosciences, Inc. (RCUS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arcus Biosciences Announces New Employment Inducement Grants - Yahoo! Finance Canada
Arcus Biosciences Announces New Employment Inducement Grants - finance.yahoo.com
Arcus Biosciences, Inc. (RCUS) Stock forecasts - Yahoo Finance Singapore
Arcus Biosciences stock trades 16.8 percent below yearly high - AD HOC NEWS
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance
(RCUS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
RCUS Looks 292.6% Overvalued on GF Value™ - GuruFocus
Cantor Fitzgerald reiterates Arcus Biosciences stock rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Arcus Biosciences stock rating - Investing.com
New kidney cancer data from 121 patients will be shared Oct. 20 - Stock Titan
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy - Yahoo Finance
2.56%
자본화:
|
볼륨(24시간):